臨床研究・開発教育学

松田 勇紀

マツダ ユウキ  (Yuki Matsuda)

基本情報

所属
藤田医科大学 医学部 臨床研究・開発教育学 准教授
(兼任)医学教育企画室 室員
(兼任)臨床研究中核病院準備室 准教授
東京慈恵会医科大学 精神医学講座 非常勤講師
学位
学士(医学)(2010年3月 藤田医科大学)
博士(医学)(2016年3月 藤田医科大学大学院)
社会健康医学修士(専門職)(2024年3月 京都大学大学院)

researchmap会員ID
B000247656

外部リンク

論文

 86
  • Yuki Matsuda, Shun Takahashi
    Psychiatry and Clinical Neurosciences Reports 2026年8月  査読有り筆頭著者責任著者
  • Yuki Matsuda, Kenji Sakuma, Shun Igarashi, Daisuke Hayashi, Shinsuke Kito, Taro Kishi
    Alpha Psychiatry 2026年8月  査読有り筆頭著者責任著者
  • Yuki Matsuda, Yuta Suzuki
    Psychiatry and clinical neurosciences 80(8) 703-704 2026年8月  査読有り筆頭著者責任著者
    This article relates to Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia.
  • Yuki Matsuda, Yuta Suzuki, Aran Tajika, Taro Kishi
    Psychiatry and clinical neurosciences 2026年7月8日  査読有り筆頭著者責任著者
    This article relates to Model choice in meta-analysis should not be driven by Cochran's Q test.
  • Hiroyoshi Takeuchi, Naoki Hashimoto, Yoshiteru Takekita, Maeri Yamamoto, Jun Miyata, Kazutaka Ohi, Hiroyuki Muraoka, Michihiko Koeda, Itaru Miura, Kazuto Oya, Yasushi Kawamata, Yuta Yoshino, Yoji Hirano, Hikaru Hori, Genichi Sugihara, Junya Matsumoto, Satsuki Ito, Ryo Sawagashira, Atsuhito Toyomaki, Hayato Watanabe, Yosuke Koshikawa, Toshiya Funatsuki, Yuki Tanaka, Shinichiro Nakajima, Saki Homma, Yuka Kaneko, Yutaro Shimomura, Keita Kawai, Chikako Kawai, Manabu Kubota, Hiroyuki Igarashi, Sadao Otsuka, Daisuke Fujikane, Yuhei Suzuki, Yuri Kobayashi, Yuki Matsuda, Tomoko Kitajima, Shinichiro Ochi, Hideaki Yasuda, Ryota Hashimoto
    Psychiatry and clinical neurosciences 2026年3月10日  査読有り
    AIM: We aimed to examine the psychometric properties of the second version of the Brief Evaluation of Psychosis Symptom Domains (BE-PSD-V2.0) and its correspondence with the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity scale (CGI-S) scores. METHODS: This cross-sectional study was conducted at 18 institutes in Japan. We performed correlational analyses to test the convergent and divergent validity of the BE-PSD-V2.0. Inter-rater reliability was assessed using intraclass correlation coefficients (ICCs). The equipercentile equating method was employed to examine the linking of the BE-PSD-V2.0 with the PANSS and the CGI-S. RESULTS: A total of 353 patients with schizophrenia spectrum disorders were included. Spearman's rank correlation coefficients between the BE-PSD-V2.0 item scores and their corresponding PANSS factor scores ranged from 0.64 to 0.86, indicating sufficient convergent validity. These specific correlation coefficients were consistently the highest among all item-to-factor comparisons, indicating sufficient divergent validity. In 34 patients, ICCs for the BE-PSD-V2.0 item and total scores ranged from 0.60 to 0.94, showing sufficient inter-rater reliability. Conversion tables were established between the BE-PSD-V2.0 total score and the PANSS total score, between the BE-PSD-V2.0 total score and the CGI-S score, and between the BE-PSD-V2.0 item scores and their corresponding PANSS factor scores. A correspondence between symptomatic remission criteria using the PANSS and BE-PSD-V2.0 was confirmed. CONCLUSIONS: The BE-PSD-V2.0 possesses sufficient psychometric properties and corresponds to the PANSS and CGI-S. It is a sound and reliable brief rating scale for assessing symptoms in schizophrenia spectrum disorders, and its established conversion correspondences facilitate score interpretation within existing clinical paradigms for both clinical practice and research.

主要なMISC

 112

書籍等出版物

 3

講演・口頭発表等

 141

担当経験のある科目(授業)

 9

共同研究・競争的資金等の研究課題

 6

学術貢献活動

 9

主要な社会貢献活動

 19

メディア報道

 5

その他

 1